CAMK2G and Ventricular arrhythmia: Our data in atrial myocytes also complements findings that CaMKII inhibition reduces the risk of ventricular arrhythmias [14,15,47,50] suggesting that targeting CaMKII signaling has a considerable potential for cardiac therapies.